BioNTech reiterates presence in Africa; WuXi eyes first Chinese vaccine plant; Chinese drugmaker blocks FDA checks

Wel­come to End­points’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls, and more.

This week, we look in­to WuXi Bi­o­log­ics’ first vac­cine man­u­fac­tur­ing fa­cil­i­ty in Chi­na, as well as BioN­Tech’s re­it­er­a­tion of its con­tin­ued work in Africa.

We al­so ze­ro in on the lat­est gov­ern­ment ac­tion, which sees CSL Se­qirus land a four-year deal with the UK gov­ern­ment to sup­ply emer­gency vac­cines, and Sau­di Ara­bi­an plans for a new $133 mil­lion vac­cine man­u­fac­tur­ing fa­cil­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.